Myo-Inositol for PCOS and Insulin Resistance

If there’s one supplement-condition pairing where the evidence is genuinely compelling, it’s myo-inositol for PCOS. This isn’t hype – it’s backed by multiple meta-analyses, recommended in clinical guidelines, and has a clear mechanistic rationale.

What Is Myo-Inositol?

Myo-inositol is one of nine stereoisomers of inositol, a cyclic sugar alcohol. It functions as a second messenger in insulin signaling – essentially, it helps carry insulin’s signal from the cell surface to the cell interior. It also plays roles in follicle-stimulating hormone (FSH) signaling in the ovaries.

Your body makes myo-inositol from glucose, and you get some from food (fruits, beans, grains). But in PCOS, the conversion and utilization of myo-inositol appears to be disrupted.

The PCOS Connection

Polycystic ovary syndrome (PCOS) affects 8-13% of reproductive-age women. Insulin resistance is a core feature – present in 50-70% of women with PCOS regardless of body weight. This insulin resistance drives:

• Excess androgen production (? acne, hirsutism, hair loss)
• Irregular ovulation (? infertility, irregular periods)
• Metabolic dysfunction (? weight gain, difficulty losing weight)

What the Evidence Shows

Meta-Analyses

• Unfer et al. (2012): Meta-analysis of 6 RCTs. Myo-inositol 4 g/day significantly improved HOMA-IR, reduced testosterone, increased SHBG, improved ovulation rates in PCOS.

• Zheng et al. (2017): Meta-analysis of 10 RCTs (601 PCOS women). Myo-inositol significantly reduced fasting insulin, HOMA-IR, total testosterone, and androstenedione vs. placebo. Also improved BMI slightly.

• Pundir et al. (2018): Cochrane systematic review. Found myo-inositol may improve ovulation rate and menstrual regularity in PCOS, but called for more high-quality trials.

Key Individual Trials

• Costantino et al. (2009): 42 PCOS women. Myo-inositol 4 g/day for 12 weeks ? 72% ovulation rate vs. 10% placebo.

• Genazzani et al. (2008): 20 overweight PCOS women. 12 weeks of myo-inositol 4 g/day ? significant reduction in insulin, LH, testosterone, and improvement in insulin sensitivity.

The 40:1 Ratio

D-chiro-inositol (DCI) also has insulin-sensitizing properties, but in the ovaries, too much DCI can paradoxically impair oocyte quality. Facchinetti et al. (2015) proposed the 40:1 myo-inositol to D-chiro-inositol ratio, which mirrors physiological levels and appears to optimize both metabolic and reproductive outcomes. This is now the standard recommendation.

Dosing

• Standard: 4 g myo-inositol + 100 mg D-chiro-inositol daily
• Timing: Usually split into 2 doses (2 g + 50 mg twice daily), often taken with food
• Duration: Benefits typically appear within 3-6 months. Ovulation improvements may be seen earlier.

Beyond PCOS

Emerging evidence suggests inositol may benefit:

• Gestational diabetes: A 2016 meta-analysis (D’Anna et al.) found myo-inositol 4 g/day reduced gestational diabetes incidence in at-risk women by ~60%. Promising but needs more data.
• General insulin resistance/prediabetes: A 2020 trial showed HOMA-IR improvement in prediabetic individuals. Early-stage evidence.
• Metabolic syndrome: Small trials showing improvements in lipids and glucose markers. Not yet convincing.

Safety

• Extremely well tolerated. Side effects are minimal (occasional mild GI discomfort at high doses).
• Safe during pregnancy (actively being studied as a gestational diabetes preventive)
• No known drug interactions
• Not a hormone – it’s a natural metabolite your body already produces

What It Won’t Do

• Won’t cure PCOS (nothing does – it’s managed, not cured)
• Won’t replace metformin for everyone (some women need pharmaceutical intervention)
• Won’t overcome a poor diet/sedentary lifestyle
• Won’t work immediately – give it 3+ months

Honest Take

Myo-inositol for PCOS is one of the rare cases where a supplement has enough evidence to be included in professional clinical guidelines (Italian PCOS consensus, International Evidence-based Guideline for PCOS 2023). It’s safe, affordable, and addresses a genuine mechanistic deficit. If you have PCOS with insulin resistance, this should be near the top of your list – alongside lifestyle modification and medical supervision.

For the broader insulin sensitivity supplement picture, see our insulin sensitivity guide.

FAQ

Does myo-inositol help PCOS?

Yes – myo-inositol is the most evidence-backed non-prescription supplement for PCOS. Multiple large RCTs show it improves insulin sensitivity, restores menstrual regularity, reduces testosterone, lowers LH/FSH ratio, and improves fertility outcomes. At 2-4 g/day (alone or combined with D-chiro-inositol at 40:1), it is a legitimate medical-grade supplement for PCOS management.

What is the best myo-inositol dose for PCOS?

The most studied dose is 4 g/day myo-inositol, often divided into two 2 g doses with meals. The 40:1 myo-inositol:D-chiro-inositol combination (e.g., 4 g myo-inositol + 100 mg DCI) appears superior to myo-inositol alone in some comparative trials. Results typically begin within 3 months for hormonal markers and up to 6 months for menstrual cycle normalization.

Is myo-inositol the same as metformin?

No – they work through different mechanisms but share insulin-sensitizing effects. Myo-inositol targets the inositol phosphoglycan second-messenger pathway specifically; metformin inhibits hepatic glucose production via AMPK. Some RCTs show comparable effects on ovulation rates and testosterone, but myo-inositol has better tolerability. Metformin has broader metabolic evidence and is appropriate for more severe insulin resistance.

Can you take myo-inositol if you don’t have PCOS?

Yes – myo-inositol has evidence for insulin resistance, anxiety (as a GABA signaling modulator), and thyroid function support beyond PCOS. The effects are modest in non-PCOS populations. Some women take it for general hormone balance or cycle support without a PCOS diagnosis; this is safe but effects will be less pronounced than in PCOS where the inositol signaling defect is the specific target.

References

• Myo-inositol improves developmental competence and reduces oxidative stress in porcine parthenogenetic embryos. Frontiers in veterinary science. 2024. PMID: 39735584.
• Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, et al (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of clinical endocrinology and metabolism. PMID: 38163998.
• Pundir J et al. (2018) Inositol for PCOS. Cochrane Database Syst Rev.
• Costantino D et al. (2009) Myo-inositol and ovulation in PCOS. Eur Rev Med Pharmacol Sci.
• Genazzani AD et al. (2008) Myo-inositol and hormone profile in PCOS. Gynecol Endocrinol.
• Facchinetti F et al. (2015) Inositol ratios in PCOS. Gynecol Endocrinol.
• D’Anna R et al. (2016) Myo-inositol and gestational diabetes prevention. Diabetes Metab Res Rev.

Related Articles

• Best Metabolic Health Supplement Stacks in 2026: Optimize Blood Sugar, Insulin Sensitivity Energy
• Best Metabolic Health Supplements in 2026: Blood Sugar, Insulin Sensitivity Fat Metabolism
• Chelation Therapy in 2026: Legitimate Uses, Supplement Hype, and What the Evidence Actually Shows
• Best Vitamin D3 + K2 Supplements for Bone and Heart Health in 2026: What the Evidence Actually Shows

Sources

• Inositol for PCOS: Systematic Review and Meta-Analysis for 2023 International PCOS Guidelines (2024)
• Myo-Inositol Effects in Women With PCOS: A Meta-Analysis of RCTs (2017)
• Efficacy of Myo-Inositol on Metabolic and Endocrine Outcomes in PCOS: Meta-Analysis of RCTs (2022)
• Glucose-Lowering Effect of Berberine on Type 2 Diabetes: Systematic Review (2022)
• Berberine on Glycemic Control: Umbrella Meta-Analysis of RCTs (2023)